



Attorney Docket ACC 31

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: HENDERSON

SERIAL NO.: 09/845,741

FILED: MAY 1, 2001

TITLE: USE OF MEDIUM CHAIN TRIGLYCERIDES
FOR THE TREATMENT AND PREVENTION
OF ALZHEIMER'S DISEASE AND OTHER
DISEASES RESULTING FROM REDUCED
NEURONAL METABOLISM

EXAMINER:

ART UNIT: 1614

CONFIRMATION NO: 3451

TECH CENTER 1600/2900

OCT 14 2003

RECEIVED

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant calls the Examiner's attention to the patents and publications listed on the attached Form PTO-1449, copies enclosed, which may be material to examination of the above identified application.

TIME OF TRANSMITTAL

This Information Disclosure Statement is being submitted under 37 CFR § 1.97(c). This Statement is filed after three months from the filing date of the national application, after three months from the date of entry into national stage under 37 CFR § 1.491, after the mailing of a first Office Action on the merits, or after the mailing of a first Office Action after the filing of a requested for continued examination under 37 CFR § 1.114, but before the mailing date of any of:

- (a) a final action under 37 CFR § 1.113;
- (b) a notice of allowance under 37 CFR § 1.311; or
- (c) an action that otherwise closes prosecution in the application.

37 CFR 1.8

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on 10/7/03

Signature: Tasha L. Cove

Name: Tasha L. Cove



Certification under 37 CFR § 1.97(e)(2)

The undersigned hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

It is believed that no fees are due with this submission. If this is in error, please charge Deposit Account No. 19-5117. The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. This listed patents and publications are believed of interest herein and consideration and citation of as interest by Examiner is respectfully requested.

Respectfully submitted,

Date: October 7, 2003

Darla G. Yoerg, #48,053
Swanson & Bratschun, L.L.C.
1745 Shea Center Drive, Suite 330
Highlands Ranch, Colorado 80129
Telephone: 303-268-0066
Facsimile: 303-268-0065

RECEIVED
OCT 14 2003
TECH CENTER 1600/2900

cc: S. Orndorff
S:\Client Folders\Accera\ACC01\UTILITY\Supp IDS.doc

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

List of Information Cited by Applicant
Page 1 of 1

ATTY. DOCKET NO. ACC.01	SERIAL NO. 09/845,741
APPLICANT HENDERSON	
FILING DATE MAY 1, 2001	GROUP 1614

U.S. PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB-CLS	FILE DATE
	AA	4407821	10/04/83	Mendy			

FOREIGN PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB CLS	TRANS ?
	AB	6-287138	6/10/1994	Japan			
	AC						
	AD						
	AE						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	AF	Patent Abstracts of Japan, Abstract for Publication No. 06-287138, (9/22/03)
	AG	Dialog Results (9/22/03) Agent for Prevention and/or therapeutics of Alzheimer's disease-contg. Triglyceride of 8-10 carbon fatty acids as active ingredient, Translation of Publication No. 06-287138
	AH	
	AI	
	AJ	
	AK	
	AL	
	AM	
	AN	
EXAMINER _____ DATE CONSIDERED _____		
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>		

S:\Client Folders\Accera\ACC01\UTILITY\Supp IDS.doc

RECEIVED
OCT 14 2003
TECH CENTER 1600/2900